Andrea S. James
CIK: 0002027010
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Insight Molecular Diagnostics Inc.
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Mar 26, 2026IMDX
Insight Molecular Diagnostics Inc.
Exercise(M)Direct28.3K shares- - Mar 26, 2026IMDX
Insight Molecular Diagnostics Inc.
Tax Payment(F)Direct11.3K shares at avg. $4.11$46K - Oct 31, 2025IMDX
Insight Molecular Diagnostics Inc.
Tax Payment(F)Direct12.2K shares at avg. $6.01$73K - Oct 31, 2025IMDX
Insight Molecular Diagnostics Inc.
Exercise(M)Direct50K shares- - Oct 31, 2025IMDX
Insight Molecular Diagnostics Inc.
Disposition(D)DirectRestricted Stock Units
50K shares- - Sep 28, 2025IMDX
Insight Molecular Diagnostics Inc.
Award(A)DirectOption to Purchase Common Stock
235K shares- - Mar 26, 2025OCX
Oncocyte Corp
Award(A)DirectRestricted Stock Units
113.2K shares- - Feb 7, 2025OCX
Oncocyte Corp
Purchase(P)Direct97.6K shares at avg. $2.05$200K - Dec 5, 2024OCX
Oncocyte Corp
Purchase(P)Direct20K shares at avg. $2.29$46K - Oct 11, 2024OCX
Oncocyte Corp
Award(A)DirectOptions to Purchase Common Stock
200K shares- - Oct 11, 2024OCX
Oncocyte Corp
Award(A)DirectRestricted Stock Units
100K shares- - Oct 2, 2024OCX
Oncocyte Corp
Purchase(P)Direct33.7K shares at avg. $2.97$100K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 26, 2026 | IMDX Insight Molecular Diagnostics Inc. | Exercise(M) | 28,302 | - | $0 | Direct |
| Mar 26, 2026 | IMDX Insight Molecular Diagnostics Inc. | Tax Payment(F) | 11,298 | $4.11 | $46,435 | Direct |
| Oct 31, 2025 | IMDX Insight Molecular Diagnostics Inc. | Tax Payment(F) | 12,175 | $6.01 | $73,172 | Direct |
| Oct 31, 2025 | IMDX Insight Molecular Diagnostics Inc. | Exercise(M) | 50,000 | - | - | Direct |
| Oct 31, 2025 | IMDX Insight Molecular Diagnostics Inc. | Disposition(D) Restricted Stock Units | 50,000 | - | - | Direct |
| Sep 28, 2025 | IMDX Insight Molecular Diagnostics Inc. | Award(A) Option to Purchase Common Stock | 235,000 | - | - | Direct |
| Mar 26, 2025 |  OCX Oncocyte Corp | Award(A) Restricted Stock Units | 113,207 | - | - | Direct |
| Feb 7, 2025 | OCX Oncocyte Corp | Purchase(P) | 97,561 | $2.05 | $200,000 | Direct |
| Dec 5, 2024 | OCX Oncocyte Corp | Purchase(P) | 20,000 | $2.29 | $45,800 | Direct |
| Oct 11, 2024 | OCX Oncocyte Corp | Award(A) Options to Purchase Common Stock | 200,000 | - | - | Direct |
| Oct 11, 2024 | OCX Oncocyte Corp | Award(A) Restricted Stock Units | 100,000 | - | - | Direct |
| Oct 2, 2024 | OCX Oncocyte Corp | Purchase(P) | 33,670 | $2.97 | $100,000 | Direct |
1-12 of 12 transactions
About James Andrea S.
James Andrea S. (SEC CIK 0002027010) files insider reports with the SEC as Chief Financial Officer of Insight Molecular Diagnostics Inc. (IMDX).
Signal8 holds 9 ownership filings by James Andrea S., all Form 4s, filed between Oct 4, 2024 and Mar 30, 2026. Those filings report 12 transactions, from Oct 2, 2024 to Mar 26, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on James Andrea S.'s filings is in NASHVILLE, TN.
Recent filings by James Andrea S.
- Mar 26, 2026: Option exercise of IMDX shares (Form 4, code M).
- Mar 26, 2026: Tax withholding of IMDX shares (Form 4, code F).
- Oct 31, 2025: Tax withholding of IMDX shares (Form 4, code F).
- Oct 31, 2025: Option exercise of IMDX shares (Form 4, code M).
- Oct 31, 2025: Disposition to issuer transaction of IMDX derivative securities (Form 4, code D).
Other insiders filing for Insight Molecular Diagnostics Inc. (IMDX)
- SILVERMAN LOU, Director
- Last Andrew J., Director
- Arno Andrew, Director
- BROADWOOD PARTNERS, L.P., 10% Owner
- Liu James Yang, VP ACCT, Cntlr, Treasurer, PAO
- Riggs Josh, CEO and President